West Pharma (WST) Tops Q2 EPS by 33c, provides guidance

West Pharma (NYSE: WST) reported Q2 EPS of $1.84, $0.33 better than the analyst estimate of $1.51. Revenue for the quarter came in at $766.5 million versus the consensus estimate of $725.26 million.

GUIDANCE:

West Pharma sees FY2025 EPS of $6.65-$6.85, versus the consensus of $6.27.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Reading (RDI) Tops Q2 EPS by 4c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c